Annals of Oncology 13:1029-1035, 2002
© 2002 European Society for Medical Oncology
Original Paper |
Phase II trial of thalidomide in renal-cell carcinoma
1 Institut Gustave Roussy, Villejuif; 2 Kremlin Bicêtre Hospital, Kremlin Bicêtre, France
Received 1 February 2002; accepted 26 February 2002
Background:
Thalidomide has been reported to yield anti-tumor activity in cancer. We performed a phase II trial of this drug in patients with metastatic renal cell carcinoma to determine its efficacy.
Patients and methods:
Patients with proven metastatic renal cell cancer, measurable progressive disease and a performance status of 0–2 were enrolled in this study. Thalidomide was given daily at a starting dose of 400 mg, followed by a 400 mg increment to 800 mg and then to 1200 mg with 6–12 weeks at each dose level. The response rate at 6 months was the primary end point. Toxicity, overall survival, tumor vascularization depicted on color Doppler ultrasonography and serum vascular endothelial growth factor, basic fibroblast growth factor, interleukin-12 and tumor necrosis factor-
levels were secondary end points.
Results:
Forty patients were enrolled. Two partial responses were observed (5%) and disease remained stable in nine patients after 6 months. Median survival was 10 months. Toxicity was high, with frequent manifestations of fatigue, constipation and lethargy. The incidence of neuropathy detected on electromyography (EMG) attained 70% at 6 months, and 100% in patients on thalidomide for 12 months. Nine patients developed venous thromboembolism during the first 12 weeks of treatment, and three of them experienced pulmonary embolism. One unexpected (and unexplained) death occurred.
Conclusions:
Despite undisputed, albeit marginal, activity in renal cell cancer, high-dose thalidomide cannot be recommended using this schedule since the level of toxicity is high.
Key words: anti-angiogenic drugs, renal cancer, thalidomide
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Palumbo, T. Facon, P. Sonneveld, J. Blade, M. Offidani, F. Gay, P. Moreau, A. Waage, A. Spencer, H. Ludwig, et al. Thalidomide for treatment of multiple myeloma: 10 years later Blood, April 15, 2008; 111(8): 3968 - 3977. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Harrison, E. Obermueller, N. R. Maisey, S. Hoare, K. Edmonds, N. F. Li, D. Chao, K. Hall, C. Lee, E. Timotheadou, et al. Tumor Necrosis Factor {alpha} As a New Target for Renal Cell Carcinoma: Two Sequential Phase II Trials of Infliximab at Standard and High Dose J. Clin. Oncol., October 10, 2007; 25(29): 4542 - 4549. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. McCarville, C. J. Streck, P. V. Dickson, C.-S. Li, A. C. Nathwani, and A. M. Davidoff Angiogenesis Inhibitors in a Murine Neuroblastoma Model: Quantitative Assessment of Intratumoral Blood Flow with Contrast-enhanced Gray-Scale US. Radiology, July 1, 2006; 240(1): 73 - 81. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Lee, P. M. Patel, P. J. Selby, B. W. Hancock, I. Mak, L. Pyle, M. G. James, D. A. Beirne, S. Steeds, R. A'Hern, et al. Randomized Phase II Study Comparing Thalidomide With Medroxyprogesterone Acetate in Patients With Metastatic Renal Cell Carcinoma J. Clin. Oncol., February 20, 2006; 24(6): 898 - 903. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. V. Rajkumar Thalidomide Therapy and Deep Venous Thrombosis in Multiple Myeloma Mayo Clin. Proc., December 1, 2005; 80(12): 1549 - 1551. [PDF]
|
|
|
|
 |
|
 N. Lassau, M. Lamuraglia, D. Vanel, A. Le Cesne, L. Chami, S. Jaziri, P. Terrier, A. Roche, J. Leclere, and S. Bonvalot Doppler US with perfusion software and contrast medium injection in the early evaluation of isolated limb perfusion of limb sarcomas: prospective study of 49 cases Ann. Onc., July 1, 2005; 16(7): 1054 - 1060. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. I. Rini and E. J. Small Biology and Clinical Development of Vascular Endothelial Growth Factor-Targeted Therapy in Renal Cell Carcinoma J. Clin. Oncol., February 10, 2005; 23(5): 1028 - 1043. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Kerr A word in your ear: the 2004 Annals of Oncology prizes Ann. Onc., September 1, 2004; 15(9): 1303 - 1304. [Full Text] [PDF]
|
|
|
|
|
|
V. Eleutherakis-Papaiakovou, A. Bamias, and M. A. Dimopoulos Thalidomide in cancer medicine Ann. Onc., August 1, 2004; 15(8): 1151 - 1160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. V. Rajkumar Thalidomide: Tragic Past and Promising Future Mayo Clin. Proc., July 1, 2004; 79(7): 899 - 903. [PDF]
|
|
|
|
|
|
S. Kumar, T. E. Witzig, and S. V. Rajkumar Thalidomide: Current Role in the Treatment of Non-Plasma Cell Malignancies J. Clin. Oncol., June 15, 2004; 22(12): 2477 - 2488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Wahl, T. L. Moser, and S. V. Pizzo Angiostatin and Anti-angiogenic Therapy in Human Disease Recent Prog. Horm. Res., January 1, 2004; 59(1): 73 - 104. [Abstract] [Full Text]
|
|
|
|
 |
|
 D Cosgrove Angiogenesis imaging - ultrasound Br. J. Radiol., December 1, 2003; 76(suppl_1): S43 - S49. [Full Text] [PDF]
|
|
|
|
|
|
M. Hernberg, P. Virkkunen, P. Bono, H. Ahtinen, H. Maenpaa, and H. Joensuu Interferon Alfa-2b Three Times Daily and Thalidomide in the Treatment of Metastatic Renal Cell Carcinoma J. Clin. Oncol., October 15, 2003; 21(20): 3770 - 3776. [Abstract] [Full Text] [PDF]
|
|